Supplementary Table 1. Cross-sectional association of CSF biomarkers with clinical diagnosis excluding APOE as a covariate.

	Adjusted for	MCI		AD	
	T-tau /Aβ ₄₂	Coefficients	p-values	Coefficients	p-values
α-syn	No	0.050	0.090	0.058	0.089
•		[(-0.008)-		[(-0.009)-	
		(0.11)]		(0.12)]	
	Yes	-0.046	0.086	-0.064	0.041
		[(-0.0)-(0.)]		[(-0.13)-(-	
		-		0.003)]	
pS129-α-syn	No	-0.002	0.074	-0.0003	0.84
		[(-0.005)-		[(-0.003)-	
		(0.0002)]		(0.002)]	
	Yes	-0.0007	0.58	0.002	0.25
		[(-0.003)-		[(-0.001)-	
		(0.002)]		(0.005)	
α-syn -Tau-	Yes	-0.20	0.17	-0.33	0.20
Mismatch		[(-0.54)-		[(-0.73)-	
		(0.14)]		(0.070)]	

Linear regression model is adjusted for age at baseline, and gender. Models with and without T-tau /Aβ₁₋₄₂ ratio are listed as indicated in the second column.

Supplementary Table 2. Cross-sectional association of CSF pS129- α -syn values with clinical diagnosis in subjects with HgB<200 ng/ml.

	Adjusted for	MCI		AD	
	T-tau /Aβ ₄₂	Coefficients	p-values	Coefficients	p-values
pS129-α-syn	No	-0.0026	0.0495	-0.0007	0.65
		[(-0.005)-		[(-0.004)-	
		(0.0002]		(0.001)]	
	Yes	0.0011	0.41	0.0014	0.39
		[(-0.004)-		[(-0.002)-	
		(0.002)]		(0.004)]	

Linear regression model is adjusted for age at baseline, gender, and APOE ϵ 4 presence. Models with and without T-tau /A β ₁₋₄₂ ratio are listed as indicated in the second column.

Supplementary Table 3. Association of baseline CSF pS129-α-syn values with longitudinal clinical changes in subjects with HgB<200 ng/ml. Reported as multivariate regression coefficient [95% confidence interval of coefficient] (p-value).

	Adjusted for T-tau /Aβ ₁₋ ₄₂ *time	ADAS- Cog13	Memory composite	Executive function composite	MCI progression to AD
pS129-α-syn	No	0.54	-0.55	-2.19	0.13
,		[(-2.62)-	[(-2.48)-	[(-4.96)-	[(0.00)-
		(3.71)]	(1.39)]	(0.58)]	$(2.14*10^6)$]
		(0.74)	(0.58)	(0.12)	(0.81)
	Yes	1.70	-1.32	-3.43	676.44
		[(-1.35)-	[(-3.13)-	[(-6.0)-(-	[(0.00)-
		(4.74)]	(0.49)]	0.85)]	$(41*10^{10})$]
		(0.28)	(0.15)	(0.0093)	(0.48)

Model is adjusted for age at baseline, gender, education, and APOE 4 presence. Models with and without T-tau/Aβ₁₋₄₂ ratios are listed as indicated in the second column.

Supplementary Table 4. Association of baseline CSF biomarker values with longitudinal clinical changes excluding APOE as a covariate. Reported as multivariate regression coefficient [95% confidence interval of coefficient] (p-value).

	Adjusted for T-tau /Aβ ₁₋ ₄₂ *time	ADAS- Cog13	Memory composite	Executive function composite	MCI progression to AD
α-syn	No	-0.12	0.087	0.17	0.70
•		[(-0.46)-	[(-0.12)-	[(-0.13)-	[(0.11)-(4.29)]
		(0.21)]	(0.29)]	(0.47)]	(0.70)
		(0.47)	(0.41)	(0.27)	
	Yes	-0.59	0.37	0.62	0.02
		[(-0.96)-(-	[(0.16)-	[(0.31)-	[(0.002)-(0.21)]
		0.23)]	(0.59)]	(0.93)]	(0.001)
		(0.002)	(0.0008)	(0.0001)	
pS129-α-syn	No	0.39	-0.17	-1.69	0.28
		[(-2.11)-	[(-1.81)-	[(-3.72)-	$[(7*10^{-7})-(10^5)]$
		(2.89)]	(1.46)]	(0.33)]	(0.85)
		(0.76)	(0.83)	(0.10)	
	Yes	1.45	-0.93	-2.59	96
		[(-0.88)-	[(-2.44)-	[(-4.5)-(70)]	$[(1*10^{-4})-(6*10^{7})]$
		(3.80)]	(0.58)]	(0.007)	(0.50)
		(0.22)	(0.23)		
α -syn-p-tau ₁₈₁ -Mis	Yes	-0.06	0.043	0.07	0.66
		[(-0.11)-(-	[(0.02)-	[(0.03)-	[(0.51)-(0.85)]
		0.02)]	(0.07)]	(0.10)]	(0.001)
		(0.003)	(0.001)	(0.0006)	

Model is adjusted for age at baseline, gender, and education. Models with and without T-tau/A β_{1-42} ratio are listed as indicated in the second column.